Correction

This article refers to:

Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients

Article title: Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients

Authors: Nusrat Rahman, Abhilash Janardhanan, Sahil Shikalgar, Mohammad Aslam Pirkhan, James Canner, Christopher Skipwith and Md. Noor-E-Alam

Journal: Substance Use & Misuse

DOI: https://doi.org/10.1080/10826084.2023.2275559

In the published version, the order of Tables 1, 2 and 3 was incorrect.

The correct order of tables is as follows:

The original article has been updated and published online.

Table 1. Patient demographics.

		Simulated adherence
	All	No	Yes
Total patients	3950	3539	411
Sex
Male	2170	1960	210
Female	1780	1579	201
Age
Mean	39.5	39.68	38.24
Median	38	38	38
Minimum	18	18	19
Maximum	70	70	70
Number of visits
Mean	6.33	6.17	7.75
Median	4	4	5
Minimum	2	2	2
Maximum	61	61	58
Duration in treatment (days)
Mean	110	110.82	109.67
Median	71	71	71
Minimum	2	2	5
Maximum	537	535	537

Table 2. Comparison of clinical profiles between patients with histories of single or multiple simulated adherence.

	Positive for simulated adherence
	Total	Single incidence	Multiple incidences
No. of patients	411	214	197
Median retention (days)	70	57	97
Median no. of visits	5	4	7
Maximum no. of occurrence in one patient	—	—	47
Simulated adherence as a % of total visits	36.5	17.65	48.1

Table 3. Descriptive statistics and risk factors for full sample by simulated adherence status.

			Logistic regression
Characteristic	Adherent	Simulated adherent	OR	CI (low)	CI (upper)	p
	N (%)	N (%)
Patient count	3539 (89.6)	411 (10.4)
Age M (SD)^a^,^d
19–25	148 (86.04)	24 (13.95)	1.85	0.98	3.51	.059
26–40	1961 (88.93)	244 (11.06)	1.60	0.99	2.57	.055
41–55	1140 (90.26)	123 (9.73)	1.42	0.86	2.32	.168
56–70	290 (93.54)	20(6.45)	(Ref)
Sex
Male	1960 (90.32)	210 (9.67)	(Ref)
Female	1579 (88.7)	201 (11.29)	1.15	0.93	1.41	.203
Days in treatment^b,^c
2–30 (1st quartile)	904 (91.12)	88 (8.87)	(Ref)
31–60	1747 (88.59)	225(11.40)	1.36	0.92	2.01	.125
61–180	179 (82.87)	37 (17.12)	1.82	0.96	3.47	.066
≥180	709 (92.07)	61 (7.92)	0.65	0.33	1.27	.207
Number of visits^a,^c
<5	2242 (91.36)	212 (8.63)	(Ref)
6–15	1089 (87.75)	152 (12.24)	1.55	1.13	2.13	<.01
>15	208 (81.56)	47 (18.43)	3.51	1.97	6.28	<.001
Average number of days between visits^a,^c
0–7	602 (86.00)	98 (14.00)	2.05	1.09	3.85	<.05
7–15	1204 (89.38)	143 (10.61)	1.25	0.70	2.20	.449
15–35	1341 (90.06)	148 (9.93)	1.36	0.83	2.21	.22
>35	400 (89.38)	22 (5.21)	(Ref)
Antiepileptics flag^b,^c
Medication not taken	2885 (88.63)	370 (11.36)	(Ref)
Medication taken	654 (94.10)	41 (5.89)	0.57	0.40	0.80	.001
Benzodiazepines flag
Medication not taken	3304 (89.56)	385 (10.43)	(Ref)
Medication taken	235 (90.03)	26 (9.96)	1.18	0.76	1.83	.462

^aT-test.

^bChi-square test.

^cα < 0.001.

^dα < 0.05.